Unicycive Therapeutics, Inc.
UNCY
$0.64
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -100.00% | -100.00% | -29.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -100.00% | -100.00% | -29.02% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -100.00% | -100.00% | -100.00% | -29.02% |
| SG&A Expenses | 41.60% | 28.39% | 35.01% | 33.52% | 30.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.73% | 42.56% | 37.22% | 26.72% | 12.88% |
| Operating Income | -54.60% | -47.42% | -48.72% | -37.73% | -15.08% |
| Income Before Tax | -20.25% | 18.07% | 20.68% | -26.93% | -69.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.25% | 18.07% | 20.68% | -26.93% | -69.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.25% | 18.07% | 20.68% | -26.93% | -69.14% |
| EBIT | -54.60% | -47.42% | -48.72% | -37.73% | -15.08% |
| EBITDA | -54.56% | -47.39% | -48.71% | -37.69% | -15.08% |
| EPS Basic | 62.55% | 64.18% | 63.92% | 43.77% | -34.98% |
| Normalized Basic EPS | 62.26% | 63.97% | 63.89% | 37.05% | -30.44% |
| EPS Diluted | 48.56% | 51.22% | 52.49% | 43.77% | -34.98% |
| Normalized Diluted EPS | 52.35% | 54.81% | 55.85% | 37.05% | -30.44% |
| Average Basic Shares Outstanding | 173.04% | 151.47% | 131.47% | 94.71% | 62.79% |
| Average Diluted Shares Outstanding | 230.35% | 223.28% | 224.10% | 94.71% | 62.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |